Letrozole
- Generic Name
- Letrozole
- Brand Names
- Femara, Kisqali Femara Co-pack
- Drug Type
- Small Molecule
- Chemical Formula
- C17H11N5
- CAS Number
- 112809-51-5
- Unique Ingredient Identifier
- 7LKK855W8I
- Background
Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.
Letrozole was granted FDA approval on 25 July 1997.
- Indication
Letrozole is indicated to treat postmenopausal women with hormone receptor (HR) positive early breast cancer, postmenopausal women with early breast cancer who have periviously been treated with tamoxifen, and postmenopausal women with HR+ or unknown advanced breast cancer. Letrozole, given with ribociclib, is indicated to treat pre, peri, and postmenopausal...
- Associated Conditions
- Advanced Breast Cancer, Anovulatory cycle, Epithelial Ovarian Cancer, HR+, HER2-, Advanced Breast Cancer, Stage I Breast Cancer, Metastatic HR + HER2 - breast cancer
- Associated Therapies
- -
Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ
- Conditions
- Interventions
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2020-12-04
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 79
- Registration Number
- NCT00290745
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Protocol for Women at Increased Risk of Developing Breast Cancer
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2016-06-15
- Lead Sponsor
- Carol Fabian, MD
- Target Recruit Count
- 42
- Registration Number
- NCT00291135
- Locations
- 🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States
Letrozole in Postmenopausal Women at Increased Risk for Breast Cancer
- Conditions
- First Posted Date
- 2006-01-24
- Last Posted Date
- 2007-01-19
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 60
- Registration Number
- NCT00280930
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer
- Conditions
- First Posted Date
- 2005-12-21
- Last Posted Date
- 2007-09-10
- Lead Sponsor
- Intarcia Therapeutics
- Target Recruit Count
- 200
- Registration Number
- NCT00267553
Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-12-15
- Last Posted Date
- 2020-02-12
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 622
- Registration Number
- NCT00265759
- Locations
- 🇺🇸
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis, Saint Louis, Missouri, United States
🇺🇸Doctor's Hospital of Laredo, Laredo, Texas, United States
🇺🇸M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
PTK and Letrozole in Post-menopausal Women With Advanced Breast Cancer
- First Posted Date
- 2005-12-07
- Last Posted Date
- 2013-05-07
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 4
- Registration Number
- NCT00263198
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
- First Posted Date
- 2005-11-03
- Last Posted Date
- 2016-04-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 4172
- Registration Number
- NCT00248170
- Locations
- 🇺🇸
Chattanooga Oncology and Hematology Assoicates, PC, Chattanooga, Tennessee, United States
🇺🇸Texas Cancer Center ( Medical City Dallas Hospital), Dallas, Texas, United States
🇺🇸El Paso Cancer Treatment Ctr-East, El Paso, Texas, United States
Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-11-02
- Last Posted Date
- 2012-04-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 17
- Registration Number
- NCT00247663
- Locations
- 🇯🇵
Novartis Investigative Site, Saitama, Japan
Letrozole in the Treatment of Severe and Recurrent Endometriosis
- Conditions
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2012-04-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT00240942
Letrozole in the Treatment of 1st and 2nd Line Hormone Receptor Positive Breast Cancer: Pre-therapeutic Risk Assessment
- Conditions
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2012-04-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 13
- Registration Number
- NCT00241046
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.